Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | FAP | Q12884 | 4/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223707 | 1.00 | DPP4 (0.50) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL4886578 | 0.85 | TDP1 (0.55) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL4886585 | 0.85 | TDP1 (0.55) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL1072034 | 0.85 | TDP1 (0.55) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL5223869 | 0.83 | CFD (0.42) | CFD | |
| SCHEMBL5223880 | 0.83 | CFD (0.42) | CFD | |
| Trifluoroacetic Acid SCHEMBL4895383 | 0.82 | TDP1 (0.51) | DPP4FAPDPP9KCNH2 | |
| SCHEMBL6242373 | 0.79 | TDP1 (0.59) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL14102467 | 0.78 | DPP4 (0.64) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL4913502 | 0.76 | DPP4 (0.53) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406872-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1406872-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7098239-B2 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | DPP4, DPP3, DPP9 | DPP4 1/4885DPP7 4/4885FAP 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.